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Background. A number of demographic and comorbid fac-
tors have been demonstrated to be associated with the place-
ment of arteriovenous grafts (AVG) and central venous cathe-
ters (CVC) as opposed to native arteriovenous fistulas (AVF).
However, no data are available regarding these factors in a
hemodialysis population where AVF utilization is high.
Methods. All adult patients on hemodialysis on September
30, 2001 in Australia were included in the study. Vascular
access was recorded as AVF, AVG, or CVC. Patients were
separated into incident (150 days since first dialysis) and
prevalent cohorts (150 days). Multinomial logistic regression
was used to assess factors associated with AVG and CVC use.
Results. Of the 4968 patients who were studied, 877(17%)
were classed as incident and the remainder prevalent. AVF
were present in 61% versus 77%, AVG were present in 11%
versus 19%, and CVC were present in 28% versus 4% in the
incident and prevalent cohorts, respectively (all P  0.001).
After adjustment for confounding factors, age and female gen-
der were associated with an increased frequency of AVG in
both cohorts. In addition, type I diabetes mellitus was associ-
ated with increased frequency of AVG use in the incident
cohort, whereas body mass index (BMI)30 kg/m2 and periph-
eral vascular and cerebrovascular disease were significant in
the prevalent group. For CVC, female gender, type I and II
diabetes mellitus and late referral were associated with in-
creased frequency in the incident cohort, while females, ciga-
rette smoking, and peripheral vascular disease were predictive
in the prevalent group. Significant variations in access type
were also seen depending on geographic location.
Conclusion. Certain patient characteristics such as age and
female gender, but not type II diabetes mellitus, remain signifi-
cantly associated with AVG and catheter use despite the high
prevalence of AVF use in Australia. However, the significant
variation in risk by geographic location suggests more attention
needs to be paid to physician practice patterns to increase AVF
utilization rates.
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The provision of adequate vascular access for patients
with end-stage renal disease (ESRD) on hemodialysis is
one of the most important challenges facing the clinical
nephrologist. Although the native arteriovenous fistula
(AVF) is regarded as the vascular access of first choice
given its superior patency rate [1–3] and lower mortality
risk [4, 5] compared to synthetic arteriovenous grafts
(AVG), the establishment of the AVF remains a signifi-
cant problem especially in the United States [6, 7]. In
recognition of this problem, specific vascular access guide-
lines [2, 3] and clinical performance measures have been
proposed [8].
In order to increase the overall proportion of AVF,
it is critical to identify patient characteristics that are
associated with higher rates of both AVG and central
venous catheter use. This would then enable targeting
of particular patients for a more coordinated approach
to access placement, which in turn would increase the
AVF utilization rate [7]. To this end, a number of recent
studies have identified various patient characteristics (for
example, age, female gender, and diabetes mellitus) that
are associated with a higher risk for AVG use [9–16].
The majority of such studies (with two exceptions
[13, 16]) have focused solely on cohorts from the United
States where AVF use is low (approximately 30%).
Whether these particular characteristics remain a sig-
nificant barrier to successful AVF creation in a cohort
with a high AVF utilization rate is unclear. Recent single-
center data, for example, has shown that both gender
[17] and diabetes mellitus [18] are not impediments to
successful AVF creation. We were interested in which
patient characteristics would be associated with an in-
creased risk of AVG and catheter use in a large multicen-
ter cohort with a high background AVF prevalence.
Gaining insights from a high-prevalence AVF popula-
tion could help determine which factors can be “over-
come” and give additional information that would assist
nephrologists and vascular surgeons alike in targeting
the patients most at risk of AVG (and catheter) use for
earlier AVF construction.
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The present study used vascular access data from the
Australian and New Zealand Dialysis and Transplant
Association (ANZDATA) registry, where AVF preva-
lence among hemodialysis patients is 75% [19]. The aim
of this analysis is to describe factors associated with an
increased likelihood of receiving hemodialysis via either
an AVG or a catheter in Australia. Additionally, we also
examined for differences in practice patterns between
the different states in Australia (after accounting for
differences in patient characteristics), given that geo-
graphic location has previously been shown to be a sig-
nificant factor for variation in the United States [9, 14].
METHODS
Study population
The ANZDATA registry collects information on all
patients with ESRD in Australia and New Zealand. Data
are collected at 6-month intervals in March and Septem-
ber of each year. While data on specific patient outcomes
for patients receiving ESRD therapy have been collected
since 1977, data on vascular access in hemodialysis pa-
tients have only been collected since 1999. All adult
patients (age18 years on entry to the ESRD program)
receiving hemodialysis in Australia on the September
30, 2001 were eligible to be included in this analysis.
Patients are entered in to the registry only when the
recovery of renal function is deemed unlikely by the
treating physician.
We hypothesized that differences may exist in the fac-
tors that are associated with use of an AVG or a catheter
as opposed to an AVF between incident patients starting
dialysis compared to established prevalent patients.
Therefore, we performed the main analysis with the two
populations stratified into an incident and prevalent co-
hort.
Incident patients were defined as any patient who had
commenced dialysis treatment in the 12 months prior
to September 30, 2001 and, in their first data entry in
ANZDATA registry, had been receiving dialysis for
150 days. Clinical experience suggests that the estab-
lishment of permanent vascular access in the form of an
AVF can take some months in a number of patients.
AVF requires at least 6 to 8 weeks to mature and in
some patients multiple interventions may be required to
establish a well-functioning AVF. The duration of 150
days on dialysis was chosen after assessing changes in
vascular access patterns for patients grouped in to seven
periods of 30-day dialysis duration (corresponding to
the first 6 months of dialysis and beyond). Significant
differences in access patterns were present in each 30-
day period up until 150 days of dialysis duration [19].
This was especially evident in patients who were first
referred to a nephrologist3 months prior to commenc-
ing dialysis treatment. Beyond this time point, access
patterns were no different to the entire cohort and there-
fore 150 days was chosen as the cut off point to define
the incident and prevalent patient cohorts. The prevalent
sample was defined as all patients who commenced dial-
ysis treatment 12 months prior to September 30, 2001
or if they commenced treatment in the 12 months prior
to September 30, 2001, they had been on dialysis 150
days on September 30, 2001. Dialysis duration for all
patients was calculated from the date of first dialysis
treatment.
Data collection
The vascular access in use at the time of each survey
is reported as one of four options: AVF, synthetic AVG,
permanent central venous catheter, or temporary central
venous catheter. For the purposes of this analysis, the
two central venous catheter categories have been com-
bined together so each patient could have one of the
three vascular access types entered at each survey period.
Importantly, only the access functioning in use at the
time of the survey is collected. For example, if a patient
was dialyzing via a catheter but also had an AVF in situ
that was not mature, the patient’s vascular access would
be coded as a catheter. The type of vascular access in
use at first hemodialysis treatment was not collected.
The temporary and permanent central venous catheter
codes were combined because of possible misclassifi-
cation arising from interpretation of the definitions. Tra-
ditionally, permanent catheters could be regarded as
cuffed catheters. However, we had concerns over the
interpretation of “permanent” and “temporary.” “Tem-
porary” could be regarded as either a non-cuffed “tem-
porary” catheter or any catheter in use while the patient
awaits AVF construction and/or maturation. We sus-
pected that the vast majority of Australian units would
use a cuffed catheter as this temporary access and there-
fore we could not be confident that the split between
cuffed and noncuffed catheters followed the “perma-
nent” and “temporary definitions” (definitions have now
been changed so future surveys collect “cuffed” and
“noncuffed” catheters).
The ANZDATA registry also collects information
about comorbid conditions for each patient at the start
of renal replacement therapy. The presence or absence
of coronary artery disease, peripheral vascular disease,
cerebrovascular disease, and chronic lung disease is col-
lected (as specified by the treating physician) in three
categories: no, yes, or suspected. For the purposes of
this analysis, the “yes” and “suspected” groups have
been combined. Hypertension requiring treatment, the
presence or absence of diabetes (type I or II) and ciga-
rette smoking (never, current, or former smoker) is also
collected. If the patient began dialysis treatment 3
months after being first referred to a nephrologist, this
is defined as a “late referral.” Torres Strait Islanders
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were combined with Aboriginal patients in this analysis
(Indigenous Australians).
Body mass index (BMI) was calculated from the height
and weight data and was initially modeled separately
both as a continuous and then categorical variable split
in four categories: 20 kg/m2, 20 to 24.9 kg/m2, 25 to
29.9 kg/m2, and 30 kg/m2. This was done to assess
whether both a low and high BMI could be associated
with higher risk of AVG and/or catheter use. Dry weight
at the time of the survey completion was used for the
calculation of the BMI. Duration of dialysis was also
modeled as a categorical factor, split into quartiles. All
data are collected by the treating renal units on paper-
based returns and sent to ANZDATA where it is entered
manually into the registry database.
Statistical analysis
All values are presented as median (interquartile
range) or total number (percentage). Baseline character-
istics between the incident and prevalent groups were
compared using the Mann-Whitney U test for continuous
variables and the 2 test for categorical variables. Com-
parison between the different vascular access types
within the two cohorts was performed using the Kruskal-
Wallis test for the continuous variables and the 2 test
for categorical variables.
As the type of vascular access in use at the time of
the survey could be any one of the three access types,
multinomial (polytomous) logistic regression was used
[20]. Multinomial logistic regression is an extension of
logistic regression for analysis of a nominal outcome
variable with three or more categories [20, 21]. The AVF
was used as the comparison group and all analyses were
stratified according to the incident/prevalent status ex-
cept the geographic analysis or where stated (see below).
Potential independent factors associated with access type
were first assessed separately to give crude estimates and
to assess potential confounding factors. All statistically
significant factors and any other factors thought to be
clinically important, regardless of statistical significance,
were then entered into the final model. Models were
built for each cohort separately. Additionally, potential
interactions (effect modification) between gender and
diabetes mellitus (type I and type II separately) and BMI
were assessed.
Following the creation of the final model, a second
analysis on the whole patient cohort was performed as-
sessing the different access patterns among the different
states in Australia, adjusted for differences in patient
characteristics. In the analysis of state-specific data, the
overall national proportions of the three access types
was used as the comparison given that each state does
not necessarily represent a single managing network in
its own right. We considered a finding to be statistically
significant if the two-sided P value was less than 0.05.
All analyses were conducted using Intercooled Stata 7.0
(StataCorp, College Station, TX, USA).
RESULTS
Cohort description
A total of 5516 patients were recorded as having re-
ceived hemodialysis treatment in Australia during the
12-month study period. We excluded 548 patients, 160
because as they were less than 18 years of age at their
first hemodialysis treatment and 388 because they had
died during the 12 months prior to September 30, 2001,
leaving 4968 patients were eligible for analysis. Table 1
summarizes the demographic and clinical characteristics
of the patients divided into the incident and prevalent
cohorts, respectively. The majority of patients in both
cohorts dialyzed using an AVF. AVF and AVG were
more common in the prevalent versus incident cohort,
whereas catheters were more prevalent in the incident
cohort. Incident patients were older and more likely to
have type II diabetes mellitus but had a lower prevalence
of coronary artery disease, peripheral vascular disease,
cerebrovascular disease, and lung disease. There were
no significant differences between the two groups with
respect to gender, race, BMI, late referral, hypertension,
and smoking status.
Clinical characteristics and AVG use
Results of the univariable and multivariable analysis
for AVG versus AVF are presented in Table 2, grouped
into the incident and prevalent cohorts. In the incident
cohort, females were three times more likely than males
to receive an AVG compared to an AVF. Likewise, both
increasing age and type I diabetes mellitus were also
significantly associated with an increased likelihood of
AVG use (with a greater than fourfold increase in odds
for patients with type I diabetes mellitus). In contrast to
patients with type I diabetes mellitus, those with type II
diabetes mellitus did not have an increased likelihood
of AVG use. The odds ratio (OR) for both types of
diabetes mellitus was also significantly different from
each other (Wald test, P  0.02). Coronary artery dis-
ease, peripheral vascular disease, cerebrovascular vascu-
lar disease, and both current and former smokers were
not associated with increased odds of AVG utilization.
Obese patients (BMI 30 kg/m2) were 79% more likely
to receive an AVG versus an AVF compared to non-
obese patients, although this was of borderline statistical
significance. Indigenous patients were 66% less likely to
receive an AVG compared to Caucasians. Late referral
was not associated with a significantly elevated likeli-
hood of AVG placement in the incident cohort.
Results for the prevalent cohort revealed differences
to the incident cohort. Of the factors that were associated
with a significantly increased AVG utilization in the inci-
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Table 1. Characteristics of the Australian hemodialysis population as of September 30, 2001a
Total number Incident Prevalent
Population (%)b number (%)b number (%)b P valuec
Number 4968 877 (17) 4091 (83)
Age (at ESRD entry) years 57 (43–68) 60 (47–71) 56 (42–67) 0.001
Gender
Male 2906 (58) 518 (59) 2388 (58) 0.7
Female 2062 (42) 359 (41) 1703 (42)
Race
Caucasian 3999 (80) 717 (82) 3282 (80) 0.05
Aboriginal 494 (10) 97 (11) 397 (10)
Asian 302 (6) 45 (5) 257 (6)
Maori/Pacific Islands 77 (2) 9 (1) 68 (2)
Other 96 (2) 9 (1) 87 (2)
BMI kg/m2
20 587 (13) 98 (12) 489 (13) 0.05
20–24.9 1858 (40) 335 (40) 1523 (40)
25–29.9 1385 (30) 238 (28) 1147 (30)
30–34.9 501 (11) 105 (12) 396 (11)
35 274 (6) 64 (8) 210 (6)
Late referral 1011 (22) 186 (21) 825 (22) 0.6
Duration of dialysis years 2.7 (1.2–5.4) 0.2 (0.1–0.3) 3.4 (1.9–6.1) 0.001
Vascular access
Arteriovenous fistula 3515 (74) 516 (61) 2999 (77) 0.001
Synthetic graft 816 (17) 92 (11) 724 (19)
Percutaneous catheter 415 (9) 237 (28) 178 (4)
Smoking
Never 2311 (48) 398 (46) 1913 (49) 0.3
Current 676 (14) 125 (14) 551 (14)
Former 1823 (38) 346 (40) 1477 (37)
Cause of ESRD
Diabetes mellitus 926 (19) 199 (23) 727 (18) 0.001
Glomerulonephrits 1797 (36) 246 (28) 1551 (38)
Hypertension 420 (8) 96 (11) 324 (8)
APCKD 419 (8) 64 (7) 355 (9)
Other 1406 (28) 272 (31) 1134 (27)
Diabetes mellitusd
Type I 162 (3) 38 (4) 124 (3) 0.001
Type II 1214 (25) 263 (30) 951 (24)
Coronary artery disease 2212 (45) 331 (39) 1885 (47) 0.001
Peripheral vascular disease 1590 (33) 221 (25) 1369 (34) 0.001
Cerebrovascular disease 883 (18) 122 (16) 761 (19) 0.001
Hypertension 4084 (85) 742 (85) 3342 (85) 1.0
Lung disease 859 (18) 121 (14) 738 (18) 0.001
Abbreviations are: APCKD, adult polycystic kidney disease; ESRD, end-stage renal disease; BMI, body mass index.
aResults are presented as median (interquartile range) or frequency (%)
bNumbers may not add up to total number because of missing data
cIncident versus the prevalent cohort
dDiabetes proportion overall, not as the cause of ESRD
dent cohort, age, female gender, BMI 30 kg/m2 and
indigenous racial origin had point estimates that were
essentially unchanged. However, type I diabetes mellitus
was no longer associated with an increased likelihood of
AVG use in this cohort. Patients with peripheral vascular
disease were 19% more likely to have recieved an AVG
in the prevalent cohort. Additionally patients receiving
treatment for 3.5 to 5.9 and 6 years were more likely
to dialyze with an AVG. Coronary artery disease, type II
diabetes mellitus, smoking, late referral, BMI 20 kg/m2,
Maori/Pacific Islanders, and other racial subgroups re-
mained nonsignificant in the prevalent cohort.
Clinical characteristics and catheter use
Results for each cohort regarding catheter use versus
AVF are presented in Table 3. Similar to the AVG data,
both female gender and type I diabetes mellitus had a
significantly increased likelihood of catheter use in the
incident cohort. In addition, type II diabetes mellitus
patients also had a significantly increased likelihood of
catheter use. Not surprisingly, late referral was associ-
ated with the highest likelihood of catheter use, reflecting
the need for early referral to enable fistula construction
and maturation. Racial origin was also an important fac-
tor. Despite being twice as likely to be referred late (OR
2.12, 95% CI 1.73 to 2.60, P 0.001), incident indigenous
patients were less likely to receive hemodialysis via a
catheter. Unlike the AVG data, patients with a BMI
30 kg/m2 had a lower likelihood of catheter use that
was of borderline statistical significant. Age was not a
significant factor for catheter use in this cohort.
In the prevalent cohort, the association of peripheral
Polkinghorne et al: Epidemiology of vascular access 1897
Table 2. Variables associated with arteriovenous graft versus arteriovenous fistula use in the incident and prevalent cohorts
Incident Prevalent
Variable OR (95% CI) aORa (95% CI) OR (95% CI) aORb (95% CI)
Age (at ESRD entry) years 1.02 (1.01–1.04)d 1.02 (1.01–1.04)d 1.012 (1.01–1.02)e 1.02 (1.01–1.03)e
Female gender 2.99 (1.89–4.72)e 3.22 (1.97–5.28)e 2.29 (1.94–2.70)e 2.19 (1.79–2.67)e
Race (vs. Caucasians)
Indigenous 0.34 (0.12–0.99)f 0.34 (0.12–0.99)f 0.41 (0.29–0.59) 0.32 (0.20–0.50)e
Asian 0.65 (0.21–2.03) 0.68 (0.22–2.08) 1.13 (0.82–1.55) 1.35 (0.93–1.96)
Maori/Pacific Islandsc NA NA 1.81 (1.03–3.19)f 1.59 (0.82–3.09)
Otherc NA NA 0.82 (0.46–1.47) 0.96 (0.50–1.84)
BMI kg/m2
20 1.17 (0.52–2.62) 1.15 (0.50–2.68) 1.14 (0.87–1.49) 0.92 (0.68–1.26)
20–24,9 1.0 1.0 1.0 1.0
25–29.9 1.24 (0.70–2.20) 1.48 (0.81–2.70) 1.02 (0.83–1.26) 1.09 (0.86–1.37)
30 1.71 (0.96–3.05) 1.79 (0.95–3.36) 1.74 (1.39–2.19)e 1.78 (1.37–2.32)e
Late referral 1.18 (0.66–2.13) 1.53 (0.82–2.85) 0.92 (0.75–1.14) 0.98 (0.78–1.23)
Duration of dialysis years
2 NA NA 1.0 1.0
2–3.49 NA NA 1.04 (0.82–1.34) 1.01 (0.78–1.32)
3.5–5.9 NA NA 1.50 (1.18–1.90)d 1.50 (1.15–1.94)d
6 NA NA 1.75 (1.39–2.19)e 2.02 (1.52–2.70)e
Smoking (vs. nonsmokers)
Current 0.75 (0.36–1.56) 1.46 (0.65–3.28) 0.59 (0.45–1.78) 0.89 (0.64–1.22)
Former 0.92 (0.57–1.49) 1.13 (0.67–1.91) 0.73 (0.61–0.87) 0.92 (0.74–1.14)
Diabetes mellitus (vs. nondiabetics)
Type I 2.96 (1.15–7.56)f 4.81 (1.69–13.75)d 1.11 (0.69–1.80) 1.14 (0.64–2.01)
Type II 1.27 (0.77–2.07) 1.23 (0.68–2.23) 1.04 (0.86–1.26) 0.98 (0.77–1.25)
Coronary artery disease (yes vs. no) 1.31 (0.84–2.07) 1.08 (0.62–1.90) 1.32 (1.12–1.55)d 1.04 (0.83–1.30)
Peripheral vascular disease (yes vs. no) 1.15 (0.69–1.92) 0.72 (0.38–1.36) 1.52 (1.28–1.80)e 1.25 (1.00–1.58)
Cerebrovascular disease (yes vs. no) 1.60 (0.90–2.85) 1.79 (0.92–3.49) 1.48 (1.21–1.81)e 1.37 (1.07–1.74)d
Hypertension (yes vs. no) 0.69 (0.39–1.22) NA 0.74 (0.59–0.93) NA
Lung disease (yes vs. no) 0.62 (0.29–1.33) NA 1.06 (0.86–1.31) NA
ESRD is end-stage renal disease.
aAdjusted for age, gender, race, body mass index (BMI), late referral, smoking, diabetes mellitus, coronary artery disease, peripheral vascular disease, and
cerebrovascular disease
bAdjusted for age, gender, race, body mass index, late referral, duration of dialysis, smoking, diabetes mellitus, coronary artery disease, peripheral vascular disease,
and cerebrovascular disease
cNumbers in these subgroups were too small to calculate odds ratio (OR) and confidence intervals (CI)
dP  0.01
eP  0.001
fP  0.05
vascular disease was stronger as was the effect of gender.
Current smokers were more likely to receive a catheter,
whereas there was no association between type II diabe-
tes mellitus and catheter use, in contrast to the results
of the incident cohort. Catheter use was also significantly
less likely in patients receiving dialysis for longer than
2 years and late referral was no longer a significant factor.
Age, BMI, race, coronary artery disease, and cerebrovas-
cular disease were not associated with an increased likeli-
hood of catheter use.
Gender, diabetes, and BMI interaction
Table 4 shows OR for AVG utilization in females who
were either diabetic, or had either a low or high BMI.
In the incident cohort, the combination of female gender
and diabetes mellitus had a potent effect on the odds of
AVG use, especially for type I diabetic patients. The
combination of gender and diabetes mellitus made less
of an impact in the prevalent cohort with increased rates
in type I patients only given that type II diabetes mellitus
was not a significant factor for AVG use (aOR for fe-
males is the same for females with type II diabetes melli-
tus). However, we did not find any evidence for a differ-
ential effect of diabetes mellitus on AVG use according
to gender (effect modification) in either cohort (P values
for interaction between gender and diabetes mellitus all
0.05). Similar to the diabetes mellitus results in the
incident cohort, females with a high BMI (30 kg/m2)
had a high likelihood of AVG use. This effect persisted
and remained significant in the prevalent cohort. Again,
there was no evidence for any interaction between gen-
der and BMI in either cohort (P values all 0.05).
Similar to the AVG data, the combination of female
gender and type I diabetes mellitus was a strong marker
for catheter use in the incident and, to a lesser extent,
in the prevalent cohort. The combination of a high or
low BMI with female gender was not associated with
an excessive increased risk compared to female gender
alone. We found no evidence for any significant interac-
tion between gender and diabetes mellitus and gender
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Table 3. Variables associated with catheter versus arteriovenous fistula use in the incident and prevalent cohorts
Incident Prevalent
Variable OR (95% CI) aORa (95% CI) OR (95% CI) aORb (95% CI)
Age (at ESRD entry) years 1.01 (1.001–1.02) 1.01 (0.996–1.02) 1.01 (0.99–1.02) 1.00 (0.98–1.01)
Female gender 1.44 (1.05–1.96)d 1.61 (1.13–2.29)d 1.97 (1.45–2.66)e 2.25 (1.60–3.16)e
Race (vs. Caucasians)
Indigenous 1.02 (0.63–1.64) 0.55 (0.30–1.00) 1.05 (0.65–1.68) 0.83 (0.47–1.46)
Asian 0.74 (0.35–1.55) 0.56 (0.24–1.31) 0.80 (0.40–1.59) 0.96 (0.45–2.04)
Maori/Pacific Islandsc 0.72 (0.14–3.57) 1.02 (0.19–5.40) 1.71 (0.60–4.85) 0.90 (0.21–3.88)
Otherc 1.07 (0.27–4.33) 0.98 (0.23–4.23) 0.50 (0.12–2.05) 0.61 (0.14–2.55)
BMI kg/m2
20 1.31 (0.80–2.14) 1.34 (0.79–2.27) 1.07 (0.65–1.77) 0.96 (0.57–1.61)
20–24.9 1.0 1.0 1.0
25–29.9 0.91 (0.62–1.32) 0.91 (0.61–1.37) 1.05 (0.72–1.53) 1.05 (0.71–1.56)
30 0.68 (0.43–1.07) 0.63 (0.39–1.03) 1.32 (0.84–2.06) 1.04 (0.64–1.69)
Late referral 3.26 (2.28–4.66)e 3.24 (2.00–4.77)e 1.14 (0.79–1.64) 1.12 (0.77–1.63)
Duration of dialysis years
2 NA NA 1.0 1.0
2–3.49 NA NA 0.54 (0.36–0.81)d 0.52 (0.34–0.79)d
3.5–5.9 NA NA 0.65 (0.43–0.97)f 0.63 (0.41–0.97)f
6 NA NA 0.55 (0.36–0.84)f 0.49 (0.29–0.84)f
Smoking (vs. nonsmokers)
Current 1.33 (0.85–2.07) 1.29 (0.77–2.15) 1.32 (0.85–2.06) 1.62 (1.01–2.62)f
Former 0.96 (0.67–1.35) 0.86 (0.59–1.26) 1.18 (0.84–1.66) 1.30 (0.89–1.89)
Diabetes mellitus (vs. nondiabetics)
Type I 2.92 (1.40–6.07)d 3.29 (1.47–7.35)d 2.15 (1.09–4.25)f 1.50 (0.71–3.16)
Type II 1.74 (1.25–2.42)d 1.73 (1.15–2.63)d 1.24 (0.88–1.76) 0.86 (0.56–1.32)
Coronary artery disease (yes vs. no) 1.58 (1.15–2.16)f 1.35 (0.91–2.00) 1.24 (0.92–1.67) 0.94 (0.63–1.38)
Peripheral vascular disease (yes vs. no) 1.70 (1.21–2.39)f 1.33 (0.86–2.05) 2.06 (1.52–2.80)e 2.21 (1.49–3.29)e
Cerebrovascular disease (yes vs. no) 1.11 (0.71–1.73) 0.77 (0.46–1.28) 1.35 (0.94–1.95) 1.12 (0.74–1.69)
Hypertension (yes vs. no) 1.00 (0.64–1.55) NA 1.05 (0.67–1.65) NA
Lung disease (yes vs. no) 1.24 (0.80–1.90) NA 1.27 (0.88–1.83) NA
ESRD is end-stage renal disease.
aAdjusted for age, gender, race, body mass index (BMI), late referral, smoking, diabetes mellitus, coronary artery disease, peripheral vascular disease, and
cerebrovascular disease
bAdjusted for age, gender, race, body mass index, late referral, duration of dialysis, smoking, diabetes mellitus, coronary artery disease, peripheral vascular disease,
and cerebrovascular disease
cNumbers in these subgroups were too small to calculate odds ratio (OR) and confidence interval (CI)
dP  0.01
eP  0.001
fP  0.05
and BMI in either cohort (P values all 0.05 in both
cohorts).
National vascular access practice patterns
Table 5 and Figure 1 present the proportion of AVG
and catheters for the whole cohort of patients divided
in to the six states and one territory (the Australian
Capital Territory data has been combined with New
South Wales). Significant variation was seen in the distri-
bution of AVG and catheter use. Using the overall na-
tional proportions as the comparison group, New South
Wales and the Australian Capital Territory had the high-
est proportion of patients with AVG at 30%. After ad-
justing for differences in demographic and comorbid fac-
tors, patients in New South Wales and the Australian
Capital Territory were four times as likely to receive
hemodialysis via an AVG. Correspondingly, patients in
Tasmania and South Australia were the least likely to
receive an AVG.
There was also a wide variation in the proportions of
catheters ranging from 4% in South Australia to 20%
in Tasmania. After adjusting for confounding factors,
the highest likelihood was seen in Western Australia.
Overall, South Australia had the lowest combined pro-
portions of AVG (6%) and catheter (4%) use, with both
adjusted OR significantly below the national average.
DISCUSSION
This study demonstrates that, despite an overall high
prevalence of AVF, there remains a particular subset of
patients who have a significantly lower probability of
receiving hemodialysis via an AVF. In addition, the pre-
viously demonstrated influence of differing practice pat-
terns seen within the United States [9, 14] on AVF utili-
zation is also evident among the different areas in
Australia. As we were able to assess the entire cohort of
patients receiving hemodialysis during the study period,
these results can be considered representative of the
trends in vascular access use in Australia. Additionally,
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Table 4. Relative risks of arteriovenous graft (AVG) and catheter use according to gender and diabetic or body mass index (BMI) group
AVG Catheter
Incident Prevalent Incident Prevalent
Variable aORa (95% CI) aORb (95% CI) aORa (95% CI) aORb (95% CI)
Female and Type I diabetes mellitusc 15.52 (4.89–49.29)e 2.48 (1.36–4.54)f 5.29 (2.25–12.43)e 3.36 (1.48–7.63)f
Female and Type II diabetes mellitusc 3.98 (1.84–8.62)e 2.14 (1.57–2.93)e 2.79 (1.61–4.83)e 1.93 (1.12–3.31)g
Female and BMI kg/m2d
20 3.72 (1.42–9.73)f 2.02 (1.42–2.86)e 2.15 (1.15–4.02)g 2.14 (1.18–3.88)g
25–29.9 4.76 (2.13–10.64)e 2.38 (1.75–3.24)e 1.47 (0.84–2.55) 2.36 (1.41–3.97)e
35 5.77 (2.63–12.62)e 3.89 (2.84–5.34)f 1.02 (0.57–1.81) 2.33 (1.32–4.11)f
aAdjusted for age, gender, race, body mass index (BMI), late referral, smoking, diabetes mellitus, coronary artery disease, peripheral vascular disease, and
cerebrovascular disease
bAdjusted for age, gender, race, body mass index, late referral, duration of dialysis, smoking, diabetes mellitus, coronary artery disease, peripheral vascular disease,
and cerebrovascular disease
cMale nondiabetic subjects are the comparison group
dMales with normal BMI (20–24.9 kg/m2) are the comparison group
eP  0.001
fP  0.01
gP  0.05
Table 5. Arteriovenous graft (AVG) and catheter use according to region for the whole patient cohort
Number of AVG aORb Catheter aORb
Region patientsa (95% CI) (95% CI)
Australia 4968 1.00 1.00
New South Wales/ACT 1663 4.36 (3.12–6.09)c 1.08 (0.84–1.39)
Victoria 1317 0.97 (0.68–1.39) 0.94 (0.73–1.21)
Queensland 712 1.87 (1.29–2.70)c 1.32 (1.01–1.73)d
South Australia 318 0.54 (0.32–0.93)d 0.34 (0.20–0.59)c
Western Australia 499 1.71 (1.15–2.54)e 2.49 (1.91–3.25)c
Tasmania 86 0.12 (0.02–0.64)d 1.79 (1.07–2.97)d
Northern Territory 189 1.17 (0.60–2.29) 0.49 (0.26–0.93)d
a184 patients did not have a location entered
bAdjusted for age, gender, race, body mass index, late referral, duration of dialysis, smoking, diabetes mellitus, coronary artery disease, peripheral vascular disease,
and cerebrovascular disease
cP  0.001
dP  0.05
eP  0.01
we have not limited the analysis to AVG and AVF alone
or catheter and AVF by collapsing vascular access types
in to a binary variable for analysis with ordinary logistic
regression thus enabling full exploitation of the data [21].
Overall, 61% of incident patients were receiving he-
modialysis via an AVF, with 28% using a catheter and
11% an AVG. The proportion of AVF increased by 16%
to 77% in the prevalent cohort with a corresponding
reduction in catheters to 4%. Although different patients
are studied in each cohort, these trends suggest that most
centers in Australia are attempting AVF construction in
the majority of patients, with a catheter used as a bridge
to maturation if necessary. This is also supported by the
fact that time on dialysis was not associated with AVG
use until it was 3.5 years’ duration. As we do not have
data on the vascular access used at first hemodialysis, the
proportion of patients commencing hemodialysis with an
AVF is not clear. However, a recent analysis of all pa-
tients who had begun hemodialysis less than 30 days
prior to their first entry into the ANZDATA registry
revealed an AVF rate of only 50% and a catheter rate
of 45% [19]. This provides strong indirect evidence that
a large number of patients do not have a mature function-
ing AVF prior to commencing hemodialysis in Australia.
In contrast, while the definition of the incident cohorts
differed (patients on dialysis 90 days were excluded),
AVF use in the recent ESRD Clinical Performances
Measures (CPM) project study was only 29% with the
catheter rates similar at 30%. There was no increase in
the AVF proportion in the prevalent sample and only a
small reduction in catheter use to 22%. The major access
of use was the AVG in both cohorts. While the two
populations were different with respect to age and the
presence of diabetes, this does provide insights into the
different approach to vascular access between the two
countries. Large variations in the proportion of patients
commencing hemodialysis with an AVF have also re-
cently been demonstrated in an analysis of Dialysis Out-
comes and Practice Patterns Study (DOPPS) data from
the United States, Europe, and Japan [22]. Therefore,
the early construction of AVF to allow sufficient time
for maturation is an important problem in a number of
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Fig. 1. Distribution of arteriovenous grafts (AVG) and catheter across
the states of Australia.
countries even in those with a high overall AVF preva-
lence.
Assessment of the differing comorbidity associations
in access type across each cohort enables inferences to
be drawn regarding overall practice patterns in Australia.
Incident type II diabetes mellitus patients had an in-
creased likelihood of catheter use coupled with no in-
creased in AVG use, suggesting that a significant number
of type II diabetes mellitus patients require the use of
catheters as a bridge to AVF maturation. Whether this
represented an increased difficulty in establishing AVF
in type II diabetes mellitus or the requirement of a longer
maturation time cannot be answered by this analysis. In
contrast, in the CPM study [14], diabetes mellitus pa-
tients had a significantly lower risk of catheter use and
a higher risk of AVG use (assuming that the majority
of patients in that study had type II diabetes). This sug-
gests the opposite clinical scenario where diabetes melli-
tus patients are preferentially receiving an AVG first
instead of an AVF [14]. Diabetes mellitus has been asso-
ciated with higher rates of AVG use in other studies
from the United States [9, 11–14] and Europe [13]. Oth-
ers have shown that it is possible to achieve the same
proportion of AVF in patients with diabetes mellitus as
nondiabetic patients [23, 24]. Of concern was the risk
of AVG in incident type I diabetic patients (although
numerically they are a relatively small number of pa-
tients), especially if the patients were female. As previ-
ous studies did not separate type I and II diabetes, it
is unclear whether this is reflective of local Australian
practice or a more general effect of type I diabetes melli-
tus. Clearly, this group requires further attention to in-
crease AVF rates in Australia.
In contrast to type II diabetes mellitus, we found that
subjects with a BMI 30 kg/m2 had an increased likeli-
hood of AVG use of similar magnitude in both cohorts,
without any increase in the odds of catheter use. Thus
unlike the type II diabetic patients, AVG seem to be
inserted in preference to attempting AVF in this group.
Obesity has also been shown previously to be a signifi-
cant risk factor for AVG use [10–14]. Peripheral vascular
disease was significantly associated with AVG use in the
prevalent cohort but not in the incident cohort. This
suggests that AVF were being attempted despite the
presence of peripheral vascular disease but in the long-
term a significant number of patients required an AVG
(or catheter given that it was significant in this group as
well). The presence of significant vascular disease may
impair arterial inflow, delaying AVF maturation, and
reducing AVF longevity. Most [9, 11, 13] but not all [12]
studies from the United States have also demonstrated
an association between peripheral vascular disease and
AVG use. The independent association of cerebrovascu-
lar disease with AVG in both the cohorts has not to our
knowledge been demonstrated before. Hirth et al [9]
failed to demonstrate any association between a history
of cerebrovascular disease and AVG use, and further
study is needed to clarify whether any true association
exists. The data for coronary artery disease are also con-
sistent with three recent studies [9, 10, 12], failing to
show any association with AVG use, with the recent
DOPPS study incorporating both patients from the
United States and Europe the only exception [13].
Aboriginal (indigenous) people in Australia have been
shown to have a greater burden of comorbid disease at
the beginning of renal replacement therapy [25] and are
more likely to be referred late to a nephrologist prior
to commencing dialysis [26]. Despite these factors, they
were less likely to receive an AVG as opposed to an
AVF. The establishment of a multidisciplinary team ap-
proach to vascular access management in the Northern
Territory, which has a large proportion of the indigenous
patients [27], is likely to be a factor contributing to the
lower rates of AVG use in this subgroup. Although not
completely comparable, black race is associated with
AVG in some [10, 11, 14] but not all United States studies
[9, 12]. Black patients have also recently been shown to
have a significantly lower likelihood of catheter use at
first hemodialysis and a higher probability of permanent
vascular access placement prior to starting hemodialysis
(this study did not differentiate between AVF and AVG)
[15]. This finding has been suggested as one possible
explanation for the apparent favorable survival advan-
tage of black patients seen in the United States Renal
Data System (USRDS) database [15].
Overall, there are a number of similarities and differ-
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ences in the patterns between Australia, Europe, and
the United States. Increasing age, female gender, and
obesity are significant impediments to AVF utilization
in Australia, the United States, and Europe [9–14, 16].
Recent single-center data concerning the effect of gender
are conflicting, with one study demonstrating that the
gender differences persist even after the use of preopera-
tive vein mapping and frequent interventions to salvage
immature AVF [28], while another did not find any gen-
der differences in AVF prevalence [17]. The lack of
association of type II diabetes mellitus to AVG use seen
here and by others [18, 23], suggests that given pre-
ESRD care, AVF use can be increased in this patient
group. Taken together, these studies suggest that while
anatomic and comorbid factors are important, physician
practice patterns are also a very important determinant
in the type of access placed in different patients.
We have demonstrated that, similar to studies in the
United States hemodialysis population [9, 14], significant
differences exist in vascular access practice patterns
across the different states and territories in Australia.
This effect persisted even after accounting for differences
in patient demographics. This is important as it demon-
strates that differences over geographic location are not
just unique to the United States hemodialysis population,
especially given the different health care structures be-
tween the two countries. Explanations for the differences
between the geographic regions in Australia are likely
to be multifactorial. Physician and possibly nursing atti-
tudes are probably important (as shown in a recent study
of United States DOPPS data [29]). Differences in access
to vascular surgeons and the availability of operating
theater time may also be important determinants, espe-
cially in the construction of AVF sufficient time before
dialysis commencement. Identifying factors in centers
(or regions) that are performing well can assist the cen-
ters that are not performing as well to increase their
overall AVF rates. This has been demonstrated in Aus-
tralia in the Northern Territory, where AVF patency
rates have increased with the introduction of a multidisci-
plinary team approach to vascular access [27]. It is likely
that the ongoing DOPPS studies [30] will shed more light
on not only possible explanations for the discrepancies
between Australia, Europe, and the United States but
also in the differences in practice patterns across geo-
graphic location.
Despite being comprehensive in its data capture, there
are a number of limitations to this study. First, the data
on comorbidity are based on the opinion of the treating
physician, and not strictly defined criteria as would be
ideal. In addition, there was no information on the sever-
ity of disease, and the comorbidity data were collected
at the time of commencing dialysis (this has currently
changed where comorbidity is updated at each survey).
The data here represent only a cross-section in time
and so this analysis does not detect potential changes in
vascular access over time for individual patients; there-
fore, differing associations between the two cohorts
would need to be confirmed in a prospectively followed
group. The data set does not provide information on
AVF attempt rates in the incident patients. Thus, the
proportion of patients in whom an AVF was attempted,
failed, and subsequently received an AVG is unknown.
Also, as noted previously, the ANZDATA registry is not
currently externally audited and therefore the veracity of
the data is not assessed independently [31].
CONCLUSION
Despite a high overall prevalence of AVF use in Aus-
tralia, a significant number of patients receive an AVG
and catheter despite the known detrimental effects. Both
age and gender and late referral and gender were strong
predictors of AVG and catheter use, respectively. De-
spite a moderately high AVF prevalence in the new
patients commencing hemodialysis, a significant propor-
tion begin dialysis using a catheter. The encouraging
factor is that AVF use increases further in the prevalent
cohort. In addition, risks for both AVG and catheter
vary significantly across Australia, suggesting a role for
physician bias in permanent vascular access placement.
The provision of adequate pre-ESRD care for all pa-
tients with renal failure is required to further enhance
the utilization of AVF in Australia and in particular
reduce catheter rates in patients commencing hemodial-
ysis as renal replacement therapy.
ACKNOWLEDGMENTS
Dr. K.R. Polkinghorne is a recipient of a National Health and Medical
Research Council (NH&MRC) Medical Postgraduate Scholarship. We
are grateful to Dr. E. Villanueva for his statistical advice and to the
Australian and New Zealand renal units, patients, and staff for their
cooperation and contributions to ANZDATA.
Reprint requests to Dr. Kevan R. Polkinghorne, Department of Ne-
phrology, Monash Medical Centre, 246 Clayton Road, Clayton, Mel-
bourne, Victoria 3168, Australia.
E-mail: kevan.polkinghorne@med.monash.edu.au
REFERENCES
1. Hakim R, Himmelfarb J: Hemodialysis access failure: A call to
action. Kidney Int 54:1029–1040, 1998
2. Ethier JH, Lindsay RM, Barre PE, et al: Clinical practice guide-
lines for vascular access. Canadian Society of Nephrology. J Am
Soc Nephrol 10(Suppl 13):S297–S305, 1999
3. National Kidney Foundation: K/DOQI Clinical Practice Guide-
lines for Vascular Access: Update 2000. Am J Kidney Dis 37(Suppl
1):S137–S181, 2001
4. Dhingra RK, Young EW, Hulbert-Shearon TE, et al: Type of
vascular access and mortality in U.S. hemodialysis patients. Kidney
Int 60:1443–1451, 2001
5. Pastan S, Soucie JM, McClellan WM: Vascular access and in-
creased risk of death among hemodialysis patients. Kidney Int
62:620–626, 2002
Polkinghorne et al: Epidemiology of vascular access1902
6. Sands J, Perry M: Where are all the AV fistulas? Semin Dial 15:
146–148, 2002
7. Allon M, Robbin ML: Increasing arteriovenous fistulas in
hemodialysis patients: Problems and solutions. Kidney Int 62:1109–
1124, 2002
8. 2001. Report A: ESRD Clinical Performance Measures Project.
Am J Kidney Dis 39(Suppl 3):S4–S98, 2002
9. Hirth RA, Turenne MN, Woods JD, et al: Predictors of type of
vascular access in hemodialysis patients. JAMA 276:1303–1308, 1996
10. Allon M, Ornt DB, Schwab SJ, et al: Factors associated with the
prevalence of arteriovenous fistulas in hemodialysis patients in the
HEMO study. Hemodialysis (HEMO) Study Group. Kidney Int
58:2178–2185, 2000
11. Sehgal AR, Silver MR, Covinsky KE, et al: Use of standardized
ratios to examine variability in hemodialysis vascular access across
facilities. Medical Review Board of The Renal Network, Inc. Am
J Kidney Dis 35:275–281, 2000
12. Stehman-Breen CO, Sherrard DJ, Gillen D, Caps M: Determi-
nants of type and timing of initial permanent hemodialysis vascular
access. Kidney Int 57:639–645, 2000
13. Pisoni RL, Young EW, Dykstra DM, et al: Vascular access use
in Europe and the United States: Results from the DOPPS. Kidney
Int 61:305–316, 2002
14. Reddan D, Klassen P, Frankenfield DL, et al: National profile
of practice patterns for hemodialysis vascular access in the United
States. J Am Soc Nephrol 13:2117–2124, 2002
15. Avorn J, Winkelmayer WC, Bohn RL, et al: Delayed nephrologist
referral and inadequate vascular access in patients with advanced
chronic kidney failure. J Clin Epidemiol 55:711–716, 2002
16. Rodriguez JA, Lopez J, Cleries M, Vela E: Vascular access for
haemodialysis—An epidemiological study of the Catalan Renal
Registry. Nephrol Dial Transplant 14:1651–1657, 1999
17. Caplin N, Sedlacek M, Teodorescu V, et al: Venous access:
Women are equal. Am J Kidney Dis 41:429–432, 2003
18. Konner K: Primary vascular access in diabetic patients: An audit.
Nephrol Dial Transplant 15:1317–1325, 2000
19. Polkinghorne KR, Kerr PG: Vascular Access, in ANZDATA
Registry Report 2002, edited by Russ GR, Adelaide, Australia and
New Zealand Dialysis and Transplant Registry, 2003, pp 102–107
20. Hosmer DW, Lemeshow S: Applied Logistic Regression, New
York, John Wiley & Sons, Inc., 2000
21. Rothman KJ, Greenland S: Modern Epidiemiology, 2nd ed, Phila-
delphia, Lippincott Williams & Wilkins, 1998
22. Rayner HC, Pisoni RL, Gillespie BW, et al: Creation, cannulation
and survival of arteriovenous fistulae: Data from the Dialysis Out-
comes and Practice Patterns Study. Kidney Int 63:323–330, 2003
23. Konner K: Increasing the proportion of diabetics with AV fistulas.
Semin Dial 14:1–4, 2001
24. Konner K, Hulbert-Shearon TE, Roys EC, Port FK: Tailoring
the initial vascular access for dialysis patients. Kidney Int 62:329–
338, 2002
25. McDonald SP, Russ GR: The burden of end stage renal disease
(ESRD) among indigenous peoples in Australia & New Zealand.
Kidney Int 63(Suppl 83):S123–S127, 2003
26. Cass A, Cunningham J, Arnold PC, et al: Delayed referral to a
nephrologist: Outcomes among patients who survive at least one
year on dialysis. Med J Aust 177:135–138, 2002
27. Treacy PJ, Snelling P, Ragg J, et al: Impact of a multidisciplin-
ary team approach upon patency rates of arteriovenous fistulae.
Nephrol 7:66–71, 2002
28. Miller CD, Robbin ML, Allon M: Gender differences in out-
comes of arteriovenous fistulas in hemodialysis patients. Kidney
Int 63:346–352, 2003
29. Young EW, Dykstra DM, Goodkin DA, et al: Hemodialysis vas-
cular access preferences and outcomes in the Dialysis Outcomes
and Practice Patterns Study (DOPPS). Kidney Int 61:2266–2271,
2002
30. Goodkin DA, Mapes DL, Held PJ: The dialysis outcomes and
practice patterns study (DOPPS): How can we improve the care
of hemodialysis patients? Semin Dial 14:157–159, 2001
31. McDonald SP, Russ GR, Kerr PG, Collins JF: ESRD in Austra-
lia and New Zealand at the end of the millennium: A report from
the ANZDATA registry. Am J Kidney Dis 40:1122–1131, 2002
